The Correlation Between Mammography and Contrast-Enhanced Ultrasonography and Immunohistochemical HER-2 and nm-23 Expression in Early Intraductal Breast Carcinoma
FENG Huamei, LIU Ying, SONG Qian
Tangshan People's Hospital, Hebei Tangshan 063000, China
Abstract：Objective: To explore the correlation between molybdenum target X-ray and CUES expression in early DCIS and immunohistochemical HER-2 and nm-23 expression. Methods: A total of 80 cases of DCIS patients admitted from January 2018 and January 2020 were retrospective selected as the research object. Expression levels of immunohistochemical HER-2 and nm-23 were detected and image data were collected, which were analyzed with Spearman. Results: Among the 80 patients, there were 36 cases with high expression of HER-2, 44 cases with low expression of HER-2, 38 cases with high expression of nm-23, and 42 cases with low expression of nm-23 by immunohistochemistry. Abnormal vascular distribution, non-centric enhancement, high enhancement, non-uniform enhancement, and PI in the high HER-2 expression group were significantly higher than those in the low HER-2 expression group (P<0.05), and TTP in the high HER-2 expression group was significantly lower than that in the low HER-2 expression group (P<0.05). The proportion of non-radioactive enhancement and TTP in the high expression group of nm-23 were significantly higher than those in the low expression group of nm-23 (P<0.05), while PI was significantly lower than that in the low expression group of nm-23 (P<0.05). High expression of HER-2 was positively correlated with TTP (P<0.05), and negatively correlated with PI (P<0.05). High expression of nm-23 was negatively correlated with TTP (P<0.05), and positively correlated with PI (P<0.05). Conclusion: The characteristics of moly target X-ray and CUES are correlated with the expression levels of immunohistochemical HER-2 and nm-23, and abnormal vascular distribution, enhanced centrality, high enhancement, radial enhancement, high TTP and low PI should be suspected to be high HER-2 expression, while low TTP and high PI should be suspected to be high nm-23 expression.
冯华梅, 刘颖, 宋倩. 早期乳腺导管内癌钼靶X线超声造影表现及与免疫组化HER-2 nm-23表达的关系[J]. 河北医学, 2021, 27(1): 141-145.
FENG Huamei, LIU Ying, SONG Qian. The Correlation Between Mammography and Contrast-Enhanced Ultrasonography and Immunohistochemical HER-2 and nm-23 Expression in Early Intraductal Breast Carcinoma. HeBei Med, 2021, 27(1): 141-145.
[1] 石磊,陈占红,王晓稼.2018年美国ASCO年会晚期乳腺癌内分泌治疗进展[J].中国肿瘤临床,2018,45(18):7~9. [2] Lin Y,Fu F,Lv J,et al. Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis[J]. Medicine,2020,99(1):e18445. [3] 董赟,梅金红,黄先明,等.单双侧原发性乳腺癌HER-2基因扩增差异及与临床预后的关系分析[J].实用癌症杂志,2019,34(11):1773~1775. [4] Victor Lago,Maisto V,Julia Gimenez-Climent,et al. Nipple-sparing mastectomy as treatment for patients with ductal carcinoma insitu:a 10-year follow-up study.[J]. Breast Journal,2018,24(3):298~303. [5] Neuner J M,Fergestrom N M,Laud P W,et al. The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence[J]. Cancer,2019,125(22):3960~3965. [6] Yang M,Li H,Li Y,et al. Identification of genes and pathways associated with MDR in MCF-7/MDR breast cancer cells by RNA-seq analysis[J]. Molecular Medicine Reports,2018,17(5):6211~6226. [7] Christian,Thomsen,Soren,et al. Estrogen receptor-α quantification in breast cancer:concordance between immunohistochemical assays and mRNA-In situ hybridization for ESR1 gene.[J]. Applied Immunohistochemistry & Molecular Morphology Aimm,2019,28(5):347~353. [8] 彭辉,李伟平,杨海峰,等.1009例乳腺癌GATA3免疫组化染色结果分析[J].临床与实验病理学杂志,2018,34(12):1369~1371. [9] Sandi,Shen,Guihua,et al. Prediction model of lymphovascular invasion based on clinicopathological factors in Chinese patients with invasive breast cancer.[J]. Medicine,2018,97(43):e12973.
2021, Vol. 27 
冀公网安备13080202000677号